Abeona Therapeutics (ABEO) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Abeona Therapeutics (ABEO) over the past year, losing 1.7% versus a loss of 17.7%. Over five years, LFCR leads with a -32.8% price change compared with -79.4% for ABEO. Abeona Therapeutics is the larger company by market cap ($253.3 million vs $241.8 million), about 1.0 times the size.
Abeona Therapeutics converts more of its revenue into profit, with a net margin of 1223.1% versus -30.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | LFCR |
|---|---|---|
| Share price | $4.43 | $6.38 |
| Market cap | $253.33M | $241.84M |
| 1-day change | -4.73% | -0.93% |
| YTD return | -15.94% | -22.00% |
| 1-year return | -17.66% | -1.69% |
| 5-year return | -79.40% | -32.84% |
| EPS (TTM) | $-1.18 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | $128.87M |
| Revenue growth (YoY) | — | +0.47% |
| Net income (latest FY) | $71.18M | $-38.72M |
| Gross margin | 73.68% | 31.27% |
| Operating margin | -1536.91% | -13.38% |
| Net margin | 1223.08% | -30.04% |
| 52-week high | $7.65 | $8.98 |
| 52-week low | $4.00 | $3.63 |
| Distance from 52-week high | -42.09% | -28.95% |
| Analyst consensus | none | hold |
| Avg. price target upside | +326.19% | -1.57% |
| Average volume | 1.40M | 330.83K |
| Shares outstanding | 57.18M | 37.91M |
| Employees | 226 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed ABEO by 16.0 percentage points over the past year.
- Abeona Therapeutics is more profitable, keeping 1223.1 cents of every revenue dollar as net income versus -30.0 cents for Lifecore Biomedical.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
ABEO vs LFCR FAQ
Which is bigger, Abeona Therapeutics or Lifecore Biomedical?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $253.33M compared with $241.84M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, ABEO or LFCR?
LFCR returned -1.69% over the past 12 months, compared with -17.66% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.